in this issue
Regions :: Western Europe :: U.K.
Oxford BioTherapeutics Licenses Lonza’s GS Gene Expression System
12:08 AM MDT | September 2, 2011 | Deepti Ramesh
Lonza says it has signed a non-exclusive license agreement with biotechnology company Oxford BioTherapeutics (OBT; Abingdon, U.K.) that will provide OBT with access to Lonza’s GS Gene Expression System. The agreement covers the research, development and commercial use of the GS system by OBT. Financial details of the deal were not disclosed. The GS Gene Expression System is used for the production of therapeutic recombinant proteins and monoclonal antibodies. Licensing of the GS Gene Expression System expands OBT’s access to technologies for its...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee